Tag: Cancer: Prostate
ASTRO: Intensity-Modulated RT, Proton Beam Therapy Have Similar Outcomes in Prostate Cancer
No differences seen for quality of life and tumor control with localized prostate cancer
No Infections Seen After Transperineal Biopsy for Prostate Cancer
Similar cancer detection rates seen for transperineal versus transrectal biopsy, but reduction in infections seen for transperineal
Omitting Biopsy With Negative MRI Reduces Detection of Clinically Insignificant Prostate Cancer
More than half of diagnoses of clinically insignificant prostate cancer eliminated by omitting biopsy in men with negative MRI
Olaparib Monotherapy Yields Good PSA Response Rates in Prostate Cancer
Response rates seen in patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy
Mental Health Utilization Increased Around Time of Prostate Cancer Diagnosis
Increase seen for both psychotropic medication and mental health service use
Baseline MRI PI-RADS Linked to Biopsy Reclassification in Prostate Cancer
Baseline MRI PI-RADS score significantly linked to early biopsy reclassification for those with low-risk, favorable intermediate-risk cancer
Mortality Risk High for Some Gleason Grade 1 Prostate Cancer Patients
Risks increased for those with percentage positive biopsies >50 percent or prostate-specific antigen >20 ng/mL
Prostate Cancer Outcomes Comparable for Transgender Women, Cisgender Men
No significant associations seen between transgender identity and metastatic presentation, high-risk localized disease
Neighborhood Disadvantage Metrics Tied to Stress Genes in Prostate Cancer
Expression of several stress-related genes increased in prostate tumors for men living in disadvantaged neighborhoods
Out-of-Pocket Costs Considerable, Increasing for Prostate Cancer Diagnostic Testing
Costs increased between 2010 and 2020 for follow-up diagnostic testing after prostate-specific antigen-based screening
